Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 6;6(30):29626-36.
doi: 10.18632/oncotarget.4988.

CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype

Eleonora Duregon  1 , Rebecca Senetta  2 , Alessandra Pittaro  2 , Ludovica Verdun di Cantogno  2 , Giulia Stella  3 , Pierpaolo De Blasi  4 , Michele Zorzetto  3 , Cristina Mantovani  5 , Mauro Papotti  1 , Paola Cassoni  2
Affiliations

CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype

Eleonora Duregon et al. Oncotarget. .

Abstract

Brain metastases develop in one-third of patients with non-small-cell lung cancer and are associated with a dismal prognosis, irrespective of surgery or chemo-radiotherapy. Pathological markers for predicting outcomes after surgical resection and radiotherapy responsiveness are still lacking. Caveolin 1 has been associated with chemo- and radioresistance in various tumors, including non-small-cell lung cancer. Here, caveolin 1 expression was assessed in a series of 69 brain metastases from non-small-cell lung cancer and matched primary tumors to determine its role in predicting survival and radiotherapy responsiveness. Only caveolin 1 expression in brain metastasis was associated with poor prognosis and an increased risk of death (log rank test, p = 0.015). Moreover, in the younger patients (median age of <54 years), caveolin 1 expression neutralized the favorable effect of young age on survival compared with the older patients. Among the radiotherapy-treated patients, an increased risk of death was detected in the group with caveolin 1-positive brain metastasis (14 out of 22 patients, HR=6.839, 95% CI 1.849 to 25.301, Wald test p = 0.004). Overall, caveolin 1 expression in brain metastasis from non-small-cell lung cancer is independently predictive of worse outcome and radioresistance and could become an additional tool for personalized therapy in the critical subset of brain-metastatic non-small-cell lung cancer patients.

Keywords: brain metastasis; caveolin 1; non-small-cell lung cancer; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1. Representative examples of two brain metastasis from lung adenocarcinoma (A, C hematoxylin & Eosin, original magnification 400X) with mild to strong membrane-cytoplasmic immunoreactivity and negative staining for Cav1 (respectively B, D original magnification 400X) and high CAV1 gene polysomy by FISH analysis (E)
Figure 2
Figure 2. Survival curves showing that grouping by histotype was not a significant predictor for survival (Log rank test, p=0.233, 2A)
Conversely, adenocarcinoma was associated with prolonged survival when other histotypes were considered together (Log rank test, p=0.056, 2B).
Figure 3
Figure 3. Survival curves demonstrating the association between Cav1 expression in brain metastasis and poor prognosis (Log rank test, p=0.015)
See this image and copyright information in PMC

References

    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–2872. - PubMed
    1. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S, Panel M. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25:1475–1484. - PubMed
    1. Baykara M, Kurt G, Buyukberber S, Demirci U, Ceviker N, Algin E, Coskun U, Aykol S, Emmez H, Ozet A, Benekli M. Management of brain metastases from non-small cell lung cancer. J Cancer Res Ther. 2014;10:915–921. - PubMed
    1. Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol. 2008;20:676–684. - PubMed
    1. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–425. - PMC - PubMed

Publication types

MeSH terms